Centro Nacional de Ressonância Magnética Nuclear de Macromoléculas, Instituto de Bioquímica Médica, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ 21941-902, Brazil.
J Mol Biol. 2013 Nov 15;425(22):4479-95. doi: 10.1016/j.jmb.2013.08.001. Epub 2013 Aug 11.
Human β-defensins (hBDs) are believed to function as alarm molecules that stimulate the adaptive immune system when a threat is present. In addition to its antimicrobial activity, defensins present other activities such as chemoattraction of a range of different cell types to the sites of inflammation. We have solved the structure of the hBD6 by NMR spectroscopy that contains a conserved β-defensin domain followed by an extended C-terminus. We use NMR to monitor the interaction of hBD6 with microvesicles shed by breast cancer cell lines and with peptides derived from the extracellular domain of CC chemokine receptor 2 (Nt-CCR2) possessing or not possessing sulfation on Tyr26 and Tyr28. The NMR-derived model of the hBD6/CCR2 complex reveals a contiguous binding surface on hBD6, which comprises amino acid residues of the α-helix and β2-β3 loop. The microvesicle binding surface partially overlaps with the chemokine receptor interface. NMR spin relaxation suggests that free hBD6 and the hBD6/CCR2 complex exhibit microsecond-to-millisecond conformational dynamics encompassing the CCR2 binding site, which might facilitate selection of the molecular configuration optimal for binding. These data offer new insights into the structure-function relation of the hBD6-CCR2 interaction, which is a promising target for the design of novel anticancer agents.
人 β-防御素 (hBDs) 被认为是一种警报分子,当存在威胁时,它会刺激适应性免疫系统。除了其抗菌活性外,防御素还具有其他活性,例如吸引一系列不同类型的细胞向炎症部位趋化。我们通过 NMR 光谱学解决了 hBD6 的结构,它包含一个保守的 β-防御素结构域,后面是一个扩展的 C 末端。我们使用 NMR 监测 hBD6 与乳腺癌细胞系分泌的微泡以及源自 CXC 趋化因子受体 2(Nt-CCR2)细胞外结构域的肽之间的相互作用,这些肽具有或不具有 Tyr26 和 Tyr28 上的磺化。hBD6/CCR2 复合物的 NMR 衍生模型揭示了 hBD6 上连续的结合表面,该表面由 α-螺旋和 β2-β3 环的氨基酸残基组成。微泡结合表面与趋化因子受体界面部分重叠。NMR 自旋弛豫表明,游离的 hBD6 和 hBD6/CCR2 复合物表现出微秒到毫秒的构象动力学,包含 CCR2 结合位点,这可能有利于选择最佳的分子构象进行结合。这些数据为 hBD6-CCR2 相互作用的结构-功能关系提供了新的见解,这是设计新型抗癌药物的有前途的靶点。